Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP Phase II Trial
...-FirstCall/ -- Australian drug development company alchemia Limited today announced preliminary results from i...ipal investigator Associate Professor Peter Gibbs. alchemia CEO Dr Ramsdale said "we will be moving as quickly... and receive marketing approval from the US FDA. alchemia wishes to acknowledge the commitment and thank the...Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
...ewswire/ -- Phase II results exceed expectations - alchemia prepares for FDA talks on HyCAMP(TM) Australian drug development company alchemia Limited will commence discussions with the US Food...a was announced to the ASX on April 26 2007 alchemia Chief Executive Officer, Dr Peter Smith said, "The...Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
...rt of the team that managed the merger of Millennium and COR Therapeutics in 2001. During his period as CEO of Meditech, Ian led the negotiations with alchemia that resulted in the first merger of two publicly-traded Australian biotechnology companies." Dr. Nisbet will assume the CEO position immediately an...Alchemia Limited – New therapeutics to improve human health
Developed a process to produce carbohydrate molecules for the treatment of cancer and other diseases.ALCHEMIA s.r.l. COADIUVANTI CHIMICI DI SICUREZZA PER PRODUZIONE ...
Alchemia Consulting, LLC - Weaving People, Strategy and Accountability into Business Success ... © 2009 Alchemia Consulting LLC. All Rights Reserved. Site design ...